Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: A new vaccine candidate against an important noncultivable virus

Journal of Virology

Volumn 85, Issue 6, 2011, Pages 2942-2952

  Ma, Yuanmei ^a   Li, Jianrong ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; PROTEIN VP1; VIRUS VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACULOVIRUS; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; NOROVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; VESICULAR STOMATITIS VIRUS; VIRUS CULTURE; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, VIRAL; CALICIVIRIDAE INFECTIONS; CAPSID PROTEINS; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; GENETIC VECTORS; IMMUNOGLOBULIN A; MICE; MICE, INBRED BALB C; NOROVIRUS; T-LYMPHOCYTES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VACCINES, VIROSOME; VAGINA; VESICULOVIRUS; VIRAL VACCINES;

MAMMALIA; MIRIDAE; MUS; NOROVIRUS; VESICULAR STOMATITIS VIRUS;

EID: 79952412987     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02332-10     Document Type: Article

References (64)

1. Ball, J. M., M. E. Hardy, R. L. Atmar, M. E. Conner, and M. K. Estes. 1998. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J. Virol. 72:1345-1353.
2. Ball, L. A., C. R. Pringle, B. Flanagan, V. P. Perepelitsa, and G. W. Wertz. 1999. Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. J. Virol. 73:4705-4712.
3. Baric, R. S., et al. 2002. Expression and self-assembly of Norwalk virus capsid protein from Venezuelan equine encephalitis virus replicons. J. Virol. 76:3023-3030. (Pubitemid 34184887)
4. Bertolotti-Ciarlet, A., L. J. White, R. Chen, B. V. Venkataram Prasad, and M. K. Estes. 2002. Structural requirements for the assembly of Norwalk virus-like particles. J. Virol. 76:4044-4055.
5. Bertolotti-Ciarlet, A., S. E. Crawford, A. M. Hutson, and M. K. Estes. 2003. The 3′ end of Norwalk virus mRNA contains determinants that regulate the expression and stability of the viral capsid protein VP1: a novel function for the VP2 protein. J. Virol. 77:11603-11615.
6. Blanchard, E., D. Brand, and P. Roingeard. 2003. Endogenous virus and hepatitis C virus-like particle budding in BHK-21 cells. J. Virol. 77:3888-3889. (Pubitemid 36297311)
7. Braxton, C. L., S. H. Puckett, S. B. Mizel, and D. S. Lyles. 2010. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens. J. Virol. 84:3552-3561.
8. Buonocore, L., K. J. Blight, C. M. Rice, and J. K. Rose. 2002. Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J. Virol. 76:6865-6872.
9. Cheetham, S., et al. 2006. Pathogenesis of a genogroup II human norovirus in gnotobiotic pigs. J. Virol. 80:10372-10381. (Pubitemid 44628885)
10. Chen, R., J. D. Neill, M. K. Estes, and B. V. Prasad. 2006. X-ray structure of a native calicivirus: structural insights into antigenic diversity and host specificity. Proc. Natl. Acad. Sci. U. S. A. 103:8048-8053.
11. Clements, J. D., N. M. Hartzog, and F. L. Lyon. 1988. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 6:269-277.
12. Donaldson, E. F., L. C. Lindesmith, A. D. Lobue, and R. S. Baric. 2008. Norovirus pathogenesis: mechanisms of persistence and immune evasion in human populations. Immunol. Rev. 225:190-211.
13. Duizer, E., et al. 2004. Laboratory efforts to cultivate noroviruses. J. Gen. Virol. 85:79-87.
14. Estes, M. K., B. V. Prasad, and R. L. Atmar. 2006. Noroviruses everywhere: has something changed? Curr. Opin. Infect. Dis. 19:467-474.
15. Estes, M. K., et al. 2000. Norwalk virus vaccines: challenges and progress. J. Infect. Dis. 181:S367-S373.
16. Ezelle, H. J., D. Markovic, and G. N. Barber. 2002. Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector. J. Virol. 76:12325-12334.
17. Faber, M., et al. 2005. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J. Gen. Virol. 86:1435-1440.
18. Fellowes, O. N., G. T. Dimopoullos, and J. J. Callis. 1955. Isolation of vesicular stomatitis virus from an infected laboratory worker. Am. J. Vet. Res. 16:623-626.
19. Garbutt, M., et al. 2004. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 78:5458-5465. (Pubitemid 38581495)
20. Geisbert, T. W., et al. 2008. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26:6894-6900.
21. Guerrero, R. A., et al. 2001. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J. Virol. 75:9713-9722. (Pubitemid 32900106)
22. Guo, L., et al. 2009. A recombinant adenovirus prime-virus-like particle boost regimen elicits effective and specific immunities against norovirus in mice. Vaccine 27:5233-5238.
23. Haglund, K., et al. 2002. High-level primary CD8+ T-cell response to human immunodeficiency virus type 1 Gag and Env generated by vaccination with recombinant vesicular stomatitis viruses. J. Virol. 76:2730-2738. (Pubitemid 34184859)
24. Hanson, R. P., A. F. Rasmussen, Jr., C. A. Brandly, and J. W. Brown. 1950. Human infection with the virus of vesicular stomatitis. J. Lab. Clin. Med. 36:754-758.
25. Hardy, M. E., L. J. White, J. M. Ball, and M. K. Estes. 1995. Specific proteolytic cleavage of recombinant Norwalk virus capsid protein. J. Virol. 69:1693-1698.
26. Harrington, P. R., et al. 2002. Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles. J. Virol. 76:730-742. (Pubitemid 34033371)
27. Harris, J. P., W. J. Edmunds, R. Pebody, D. W. Brown, and B. A. Lopman. 2008. Deaths from norovirus among the elderly, England and Wales. Emerg. Infect. Dis. 14:1546-1552.
28. Iverson, L. E., and J. K. Rose. 1981. Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription. Cell 23:477-484.
29. Jiang, X., D. Y. Graham, K. Wang, and M. K. Estes. 1990. Norwalk virus genome cloning and characterization. Science 250:1580-1583.
30. Jiang, X., M. Wang, D. Y. Graham, and M. K. Estes. 1992. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J. Virol. 66:6527-6532.
31. + cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. J. Virol. 71:5060-5068.
32. Jones, S. M., et al. 2005. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11:786-790.
33. Kahn, J. S., A. Roberts, C. Weibel, L. Buonocore, and J. K. Rose. 2001. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J. Virol. 75:11079-11087.
34. Kapadia, S. U., et al. 2005. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340:174-182. (Pubitemid 41317492)
35. Kapikian, A. Z., et al. 1972. Visualization by immune electron microscopy of a 27-nm particle associated with acute infectious nonbacterial gastroenteritis. J. Virol. 10:1075-1081.
36. Kitamoto, N., et al. 2002. Cross-reactivity among several recombinant calicivirus virus-like particles (VLPs) with monoclonal antibodies obtained from mice immunized orally with one type of VLP. J. Clin. Microbiol. 40:2459-2465.
37. Koopmans, M. 2008. Progress in understanding norovirus epidemiology. Curr. Opin. Infect. Dis. 21:544-552.
38. Lawson, N. D., E. A. Stillman, M. A. Whitt, and J. K. Rose. 1995. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. U. S. A. 92:4477-4481.
39. Li, J., E. C. Fontaine-Rodriguez, and S. P. Whelan. 2005. Amino acid residues within conserved domain VI of the vesicular stomatitis virus large polymerase protein essential for mRNA cap methyltransferase activity. J. Virol. 79:13373-13384.
40. Li, J., J. T. Wang, and S. P. Whelan. 2006. A unique strategy for mRNA cap methylation used by vesicular stomatitis virus. Proc. Natl. Acad. Sci. U. S. A. 103:8493-8498.
41. Lichty, B. D., A. T. Power, D. F. Stojdl, and J. C. Bell. 2004. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol. Med. 10:210-216.
42. LoBue, A. D., J. M. Thompson, L. Lindesmith, R. E. Johnston, and R. S. Baric. 2009. Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J. Virol. 83:3212-3227.
43. + T cell epitopes. J. Virol. 84:8530-8538.
44. Majid, A. M., H. Ezelle, S. Shah, and G. N. Barber. 2006. Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle. J. Virol. 80:6993-7008.
45. Mead, P. S., et al. 1999. Food-related illness and death in the United States. Emerg. Infect. Dis. 5:607-625.
46. Petrovsky, N., and J. C. Aguilar. 2004. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 82:488-496.
47. Prasad, B. V., et al. 1999. X-ray crystallographic structure of the Norwalk virus capsid. Science 286:287-290. (Pubitemid 29484691)
48. Reuter, J. D., et al. 2002. Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J. Virol. 76:8900-8909. (Pubitemid 34864084)
49. Roberts, A., et al. 1998. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J. Virol. 72:4704-4711. (Pubitemid 28215645)
50. Roberts, A., L. Buonocore, R. Price, J. Forman, and J. K. Rose. 1999. Attenuated vesicular stomatitis viruses as vaccine vectors. J. Virol. 73:3723-3732.
51. Rose, N. F., et al. 2001. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106:539-549. (Pubitemid 32879316)
52. Sekaly, R. P. 2008. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. Exp. Med. 205:7-12.
53. Souza, M., V. Costantini, M. S. Azevedo, and L. J. Saif. 2007. A human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model. Vaccine 25:8448-8459.
54. Spearman, P. 2003. HIV vaccine development: lessons from the past and promise for the future. Curr. HIV Res. 1:101-120.
55. Tacket, C. O., M. B. Sztein, G. A. Losonsky, S. S. Wasserman, and M. K. Estes. 2003. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin. Immunol. 108:241-247.
56. Tan, G. S., et al. 2005. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Virology 331:82-93. (Pubitemid 39593635)
57. Tan, M., et al. 2009. Conservation of carbohydrate binding interfaces: evidence of human HBGA selection in norovirus evolution. PLoS One 4:e5058.
58. Tan, M., W. Zhong, D. Song, S. Thornton, and X. Jiang. 2004. E. coli-expressed recombinant norovirus capsid proteins maintain authentic antigenicity and receptor binding capability. J. Med. Virol. 74:641-649.
59. Taube, S., A. Kurth, and E. Schreier. 2005. Generation of recombinant norovirus-like particles (VLP) in the human endothelial kidney cell line 293T. Arch. Virol. 150:1425-1431.
60. Whelan, S. P., J. N. Barr, and G. W. Wertz. 2004. Transcription and replication of nonsegmented negative-strand RNA viruses. Curr. Top. Microbiol. Immunol. 283:61-119.
61. Whelan, S. P., L. A. Ball, J. N. Barr, and G. T. Wertz. 1995. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc. Natl. Acad. Sci. U. S. A. 92:8388-8392.
62. White, L. J., et al. 1996. Attachment and entry of recombinant Norwalk virus capsids to cultured human and animal cell lines. J. Virol. 70:6589-6597. (Pubitemid 26307363)
63. Xia, M., T. Farkas, and X. Jiang. 2007. Norovirus capsid protein expressed in yeast forms virus-like particles and stimulates systemic and mucosal immunity in mice following an oral administration of raw yeast extracts. J. Med. Virol. 79:74-83.
64. Zhang, X., N. A. Buehner, A. M. Hutson, M. K. Estes, and H. S. Mason. 2006. Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein. Plant Biotechnol. J. 4:419-432.